Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on July 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, sold shares of the company's common stock on July 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 27, 2023.
• A total of 3,852 shares were sold at a weighted average price of $37.29, with prices ranging from $36.80 to $37.76.
• An additional 2,143 shares were sold at a weighted average price of $38.16, with prices ranging from $37.85 to $38.57.
• Following these transactions, Dambkowski beneficially owns 294,793 shares of Apogee Therapeutics' common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity under a pre-arranged plan.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The share sales by the Chief Medical Officer could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this.

Key Dates